Welcome to Solco Healthcare

Solco Healthcare U.S., headquartered in Somerset, New Jersey, is an industry leader in marketing and distributing generic pharmaceuticals. Solco is committed to providing our customers with high quality, cost effective and innovative generic prescription medications.  Solco offers a broad range of generic prescription products in many therapeutic categories, including cardiovascular, central nervous system,  anti-infectivespain management and other products.  Solco currently markets 45 products, with over 40 products pending approval by the FDA, and a robust R&D pipeline of potential new products.  Our products are manufactured in state-of-the-art GMP facilities in the US and overseas using the highest quality assurance standards that meet the FDA regulatory requirements.   Solco is a fully owned subsidiary of Prinston Pharmaceutical, Inc. and Zhejiang Huahai Pharmaceutical, leaders in drug development and manufacturing of active pharmaceutical ingredients (API) and finished dosage products.   Together we strive to offer greater access to affordable medications that you can trust.

Solco Healthcare is a sales and marketing subsidiary of Prinston Pharmaceuticals

According to IQVIA, Solco has been listed as one of the Top 10 Fastest growing (according to total prescriptions dispensed) generic pharmaceutical companies for the last 5 years and was listed as the #1 Fast Growing Generic pharmaceutical company in 2018.

Prinston Pharmaceutical acquired Solco in 2012

Solco currently markets 45 products with an additional 40+ products pending approval by the FDA

Solco won the “2018 Small to Mid-Sized Generic Supplier of the Year Award” at ClarusOne Sourcing Services (a strategic sourcing group representing McKesson and Walmart)

Solco’s key focus is bringing to market high quality, cost effective generic prescription pharmaceutical products

Somerset Building
Prinston Labs Pic
Prinston First Shipment-1-27
Prinston logo

Developed by Prinston

Prinston Pharmaceutical Inc. engages in developing generic prescription oral solid, injectable, and semi-solid pharmaceutical products for the US market. Prinston was incorporated in 2010 in the state of Delaware.  Since its inception, Prinston Pharmaceutical has developed and marketed (under the Solco brand) an impressive group of generic products that provide patients affordable access to otherwise expensive brand name drugs. Solco was acquired by Prinston in March 2012 as the sales and marketing organization of Prinston.  This has allowed Prinston and Solco to be ranked as one of the Top-10 fastest growing generic pharmaceutical companies since 2014 and the fastest growing generic company in 2018 (source: IQVIA), a prestigious list that they have been on five years in a row.  To continue to supply high quality affordable medicine to the US market, Prinston Pharmaceutical acquired a manufacturing facility based in Charlotte, NC in January 2017.  This acquisition allowed Solco/Prinston to introduce additional American made generic products into the market, and expanded the company’s manufacturing capabilities allowing for more new product development in new therapeutic areas.

Prinston’s commitment to providing access to affordable medicine remains as it continues to invest in its R&D and manufacturing capabilities year after year with the goal of filing 10-15 generic drugs (ANDAs) with the FDA each year.  With over 40 products pending FDA approval, patients can be assured of a continuous stream of new generic products by Solco/Prinston, making it easier and more affordable for them to get the drugs they need, when they need them.

Backed By Huahai

Our history starts with Solco and Prinston’s parent company Zhejiang Huahai Pharmaceutical.  Huahai devotes itself to providing high-quality medicinal and health products around the world with the goal of improving the quality of life for all people.  Huahai is a large scale, modern pharmaceutical group that integrates formulations, active pharmaceutical ingredients (API) and intermediates, to deliver high quality generic medications throughout the world.  Founded in 1989, Huahai expanded to the United States in 2004 forming Huahai US to sell API to US pharmaceutical customers.  The company’s main therapeutic areas include generic prescription cardiovascular, central nervous system, and anti-viral products.  Huahai is considered a global leading API and finished dosage manufacturer in these areas.

Huahai is a pioneer in the China pharmaceutical industry becoming the first Chinese pharmaceutical manufacturing company to receive US FDA approval for its finished dosage product marketed in the United States.  Today, Huahai is rated as a “Green Factory” by the Ministry of Industry and Information Technology of the P.R.C., supporting its commitment to the World Environment that it proudly serves.  Huahai has two API manufacturing sites in China capable of producing 700 and 4,500 metric tons annually.  In addition, Huahai’s state-of-the-art finished dosage facility in Linhai, China is capable of producing over 20 billion tablets and capsules annually. 

In 2010, Huahai launched Prinston Pharmaceutical, a generic drug delivery company focused on developing generic prescription pharmaceutical products for the US market.  Combining Prinston’s strategic drug development capabilities with Huahai’s state of the art, high quality manufacturing capabilities created the opportunity to self-distribute its products throughout the US via the customary generic channels (i.e., wholesalers, distributors, chain stores, etc.).

In 2012, Huahai/Prinston acquired Solco Healthcare US from Legacy Pharmaceuticals.  Solco was a new generic pharmaceutical distributor, founded in 2010.   Relying on key development partners to launch its products, Solco quickly created a name for itself by offering value driven products with impeccable service and supply.  It was these key qualities and a shared vision of offering greater access to affordable medications that convinced Huahai/Prinston to acquire Solco.

Management Team

Solco’s leadership team is focused on putting its customer’s needs first.  While cost is a main driver in the generic industry, superior quality and a consistent and reliable supply of product is what continually drives the Solco team to perform at its best.  Our leadership team and employees strive to maintain and strengthen our customer relationships to ensure continued growth.

  • Hai Wang - President

    Hai is a seasoned pharmaceutical executive with over 25 years of proven experience in both generic and branded pharmaceutical industry. He has played leadership rule in business development, strategy, corporate management, licensing, operation/supply chain management, sales and marketing in the entire business spectrum from APIs to finished dosage forms. Hai heads up Solco’s business and operations. He is also a senior management team member of Prinston Pharmaceutical Inc. and Huahai US Inc. with responsibility of driving strategic growth for the Company in the finished products.

    Prior to joining Solco, Hai was the Senior Vice President in Business Development and Marketing at Prinston Pharmaceutical, Inc. He has also co-founded Huahai US, Inc. and held senior management positions there. Hai began his career as a chemist at Vintage Pharmaceutical. He then worked at Pfizer for eight years in various roles with increasing capacities. Hai holds a Bachelor of Pharmaceutical Science degree from East China University of Science and Technology, a Master of Science degree in Chemistry from East Tennessee State University, and a Master of Business Administration degree from Rensselaer Polytechnic Institute – The Lally School of Management and Technology.

  • Chris Keith - Senior Vice President, Marketing and Business Development

    Chris Keith is Solco Healthcare’s Senior Vice President of Marketing and Business Development. Chris utilizes his 25 years of sales, marketing and business development experience in helping Solco achieve its market share and profitability goals. He continues to be part of the senior management team at Prinston Pharmaceutical with the responsibility of identifying strategic opportunities for the company.

    Prior to joining Solco, Chris worked at Prinston Pharmaceutical as Vice President, Marketing and Business Development where he successfully negotiated and closed multiple generic drug development deals and several in-licensing, as well as out-licensing opportunities for Prinston. Prior to Prinston, Chris co-founded Éclat Pharmaceuticals where he served as the company’s Executive Vice President, Sales and Marketing. During his time at Éclat, Chris focused on identifying and commercializing niche brand and generic products including several 505(b)(2) injectables and various liquid narcotic products.

    Before Éclat, Chris spent 18 years with ETHEX Corporation. During his time at ETHEX, Chris held various roles but spent the majority of his time leading the marketing team as the Vice President, Marketing. Chris was responsible for directing the overall planning, design and implementation of all marketing, advertising and promotional activities relating to both current and future generic pharmaceutical products. Chris and his team were responsible for launching over 50 products with 87% of ETHEX’s products ranked #1 or #2 in market share position, while increasing net revenues $185.2 million within the last four years of his tenure.

    Chris holds a Bachelors of Science in Marketing and Management, as well as a Masters of Business Administration from the University of Missouri St. Louis.

  • David Ayres - Vice President of Sales

    Mr. Ayres joined Solco Healthcare U.S. in January of 2010. As Vice President of Sales, Mr. Ayres is responsible for sales and account management which encompasses every class of trade in the pharmaceutical industry. Since joining Solco, Mr. Ayres has been instrumental in helping Solco grow from $1MM Gross Sales in 2009 to $50MM+ in 2013. In October of 2013, David was honored to be named the Small Generic Company Trade Representative of the Year by Cardinal Health. Prior to joining Solco, Mr. Ayres spent 16 years with WellPoint Next Rx, one of the largest pharmacy benefit managers in the United States, in various capacities including his most recent position, Director of Pharmacy Procurement and Forecasting. Mr. Ayres was responsible for negotiations and management of corporate contracts for pharmacy purchasing, inclusive of manufacturers, vendors, and wholesalers with annual purchases exceeding 2 billion dollars. This responsibility included over 200 million dollars of annual generic Rx purchasing. Mr. Ayres also negotiated all contracts with almost every generic manufacturer in the Unites States and was personally accountable for supplying the Company with generic launch forecast information. Additionally, his responsibilities included management of all human resource in the Generic Pharmacy Procurement department inclusive of contract purchases and negotiations of non-pharmaceutical vendors in excess of 15 million dollars annually. Mr. Ayres currently holds a Bachelor of Science in Business Administration from the University of Phoenix.